Ocular Side Effects of Checkpoint Inhibitors

Drs. Meghan Berkenstock, Stella Kim, and Lauren Dalvin join the show again to teach us about immune checkpoint inhibitors: game changers in oncology, but with a host of ocular side effects. All eye providers will be seeing more patients on this class of medication, and our panel teaches us what to look for and how to manage it.

Additional resources: the National Comprehensive Cancer Network offers a suite of clinical practice guidelines to help clinicians manage immunotherapy ocular adverse events.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: March 7, 2024; expires March 7, 2027

Financial Disclosures:
Planner/Faculty: Dr. Young reports no relevant financial disclosures.
Faculty: Drs. Berkenstock, Kim, and Dalvin no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe how socioeconomic risk factors can impact access to corneal treatment and surgery.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.